Goldman Sachs’s Ambit Biosciences Corp AMBI Stock Holding History

Goldman Sachs’s Portfolio AMBI Stock Details AMBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-26,297	Closed	-$184K	–	6848
2013 Q2	$184K	Buy	+26,297	New	+$188K	﹤0.01%	5644

Other funds holding AMBI

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's AMBI Position: Q3 2013 in Review

Goldman Sachs sold out of Ambit Biosciences Corp (AMBI) in Q3 2013, closing a stake of 26,297 shares — an estimated $184K sold.

Goldman Sachs first reported a position in AMBI in Q2 2013 and held it in 1 quarter. The position peaked at $184K in Q2 2013. 23 funds tracked by Wall St. Rank hold AMBI as of Q3 2013.

Goldman Sachs reported no remaining Ambit Biosciences Corp position as of Q3 2013 after selling out during the quarter.
Goldman Sachs sold 26,297 Ambit Biosciences Corp shares in Q3 2013, an estimated $184K.
Goldman Sachs first reported a position in Ambit Biosciences Corp in Q2 2013 and held it in 1 quarter.
Goldman Sachs's Ambit Biosciences Corp position peaked at $184K in Q2 2013.
23 funds tracked by Wall St. Rank held Ambit Biosciences Corp as of Q3 2013.

Based on Goldman Sachs's 13F filing for Q3 2013, filed 14 Nov 2013.